(Q51017077)

English

Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.

scientific article published on 5 August 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

1 reference

based on heuristic

inferred from title

author name string

Nuttapong Ngamphaiboon

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Tracey L O'Connor

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Pooja P Advani

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Ellis G Levine

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Ellen B Kossoff

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

publication date

5 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

29

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

1495-1501

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Evaluation of direct medical costs of hospitalization for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0035-5

21 January 2018

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21818673

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-011-0035-5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21818673

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51017077&oldid=2210639880"